Bellerophon Therapeutics : Costs Associated with Exit/Dispos

UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


WASHINGTON, D.C. 20549



FORM 8-K



CURRENT REPORT



Pursuant to Section 13 or 15(d) of the Securiti...

Related Keywords

New Jersey , United States , Delaware , Washington , Parag Shah , Peter Fernandes , Martin Dekker , Company Vice , Securities Exchange , Bellerophon Therapeutics Inc , Securities Exchange Act , Exact Name , Principal Executive Offices , Zip Code , Former Name , Former Address , Changed Since Last Report , General Instruction , Securities Act , Exchange Act , Bellerophon Therapeutics , Interstitial Lung Disease , Certain Officers , Compensatory Arrangements , Chief Executive Officer , Vice President , Business Operations , Current Report , Chief Executive , Markets ,